J 2023

Nonmetastatic Rhabdomyosarcoma in Children and Adolescents: Overall Results of the European Pediatric Soft Tissue Sarcoma Study Group RMS2005 Study

BISOGNO, Gianni, Veronique MINARD-COLIN, Ilaria ZANETTI, Andrea FERRARI, Soledad GALLEGO et. al.

Základní údaje

Originální název

Nonmetastatic Rhabdomyosarcoma in Children and Adolescents: Overall Results of the European Pediatric Soft Tissue Sarcoma Study Group RMS2005 Study

Autoři

BISOGNO, Gianni, Veronique MINARD-COLIN, Ilaria ZANETTI, Andrea FERRARI, Soledad GALLEGO, Raquel Davila FAJARDO, Henry MANDEVILLE, Anna KELSEY, Rita ALAGGIO, Daniel ORBACH, van Scheltinga Sheila TERWISSCHA, Gabriela Guillen BURRIEZA, Myriam BEN-ARUSH, Heidi GLOSLI, Peter MÚDRY (203 Česká republika, domácí), Sima FERMAN, Christine DEVALCK, Anne Sophie DEFACHELLES, Johannes Hendrikus Maria MERKS a Meriel JENNEY

Vydání

Journal of clinical oncology, PHILADELPHIA, LIPPINCOTT WILLIAMS & WILKINS, 2023, 0732-183X

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30204 Oncology

Stát vydavatele

Spojené státy

Utajení

není předmětem státního či obchodního tajemství

Odkazy

Impakt faktor

Impact factor: 45.300 v roce 2022

Kód RIV

RIV/00216224:14110/23:00133412

Organizační jednotka

Lékařská fakulta

UT WoS

001030226300009

Klíčová slova anglicky

Nonmetastatic Rhabdomyosarcoma; Children

Štítky

Příznaky

Mezinárodní význam, Recenzováno
Změněno: 14. 2. 2024 09:40, Mgr. Tereza Miškechová

Anotace

V originále

Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary end point, may be published when key planned co-primary or secondary analyses are not yet available. Clinical Trial Updates provide an opportunity to disseminate additional results from studies, published in JCO or elsewhere, for which the primary end point has already been reported.The RMS2005 study included two phase III randomized trials for high-risk (HR) and observational trials for low (LR), standard (SR), and very high-risk (VHR) patients who have been partially reported. Herein, we present a comprehensive report of results achieved for the complete unselected nonmetastatic cohort and analyze the evolution of treatment in comparison with previous European protocols. After a median follow-up of 73.1 months, the 5-year event-free survival (EFS) and overall survival (OS) of the 1,733 patients enrolled were 70.7% (95% CI, 68.5 to 72.8) and 80.4% (95% CI, 78.4 to 82.3), respectively. The results by subgroup: LR (80 patients) EFS 93.7% (95% CI, 85.5 to 97.3), OS 96.7% (95% CI, 87.2 to 99.2); SR (652 patients) EFS 77.4% (95% CI, 73.9 to 80.5), OS 90.6% (95% CI, 87.9 to 92.7); HR (851 patients) EFS 67.3% (95% CI, 64.0 to 70.4), OS 76.7% (95% CI, 73.6 to 79.4); and VHR (150 patients) EFS 48.8% (95% CI, 40.4 to 56.7), OS 49.7% (95% CI, 40.8 to 57.9). The RMS2005 study demonstrated that 80% of children with localized rhabdomyosarcoma could be long-term survivors. The study has established the standard of care across the European pediatric Soft tissue sarcoma Study Group countries with the confirmation of a 22-week vincristine/actinomycin D regimen for LR patients, the reduction of the cumulative ifosfamide dose in the SR group, and for HR disease, the omission of doxorubicin and the addition of maintenance chemotherapy.

Návaznosti

MUNI/A/1395/2022, interní kód MU
Název: Personalizovaná léčba v dětské onkologii: multimodální theranostický přístup a „N-of-1 clinical trials“
Investor: Masarykova univerzita, Personalizovaná léčba v dětské onkologii: multimodální theranostický přístup a „N-of-1 clinical trials“